FDA committee recommends approval of Astellas’ Cresemba

The US Food and Drug Administration’s (FDA) Anti-infective Drugs Advisory Committee voted unanimously to recommend approval of Astellas’ investigational once-daily intravenous and oral broad-spectrum Cresemba (isavuconazonium) to treat invasive aspergillosis and mucormycosis.

Category One, Showcase, status, Uncategorized, What's Hot